A Multi-Center, Single-Dose, Multiple-Dose, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Related Constipation
Phase of Trial: Phase I/II
Latest Information Update: 03 Aug 2018
At a glance
- Drugs ENT 01 (Primary)
- Indications Constipation
- Focus Adverse reactions
- Acronyms RASMET
- Sponsors Enterin
- 24 Jul 2018 Status changed from active, no longer recruiting to completed.
- 22 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 02 Feb 2018 Planned end date changed from 1 Dec 2017 to 1 Apr 2018.